ArticleBlood vessels, thrombosis & hemostasis2025
Recombinant ADAMTS-13 for congenital and immune thrombotic thrombocytopenic purpura in pregnancy.
Article in Blood vessels, thrombosis & hemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current standards and novel concepts in thrombotic thrombocytopenic purpura.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening emergency. Congenital TTP (cTTP) and immune-mediated TTP (iTTP) are caused by an inherited severe deficiency of, or immune-mediated destruction of the ADAMTS-13 enzyme, respectively. Pregnancy is recognized as a trigger for both subtypes of this condition. Until recently, the treatment for TTP in pregnancy has involved therapeutic plasma exchange and immunosuppression or plasma infusion. Here, we report 3 cases of TTP in pregnancy: 2 women with cTTP, treated throughout pregnancy with recombinant ADAMTS-13 (rADAMTS-13), and 1 with refractory iTTP, where rADAMTS-13 was used in place of ongoing plasma exchange. All pregnancies resulted in excellent fetomaternal outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.